JP2018524373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524373A5 JP2018524373A5 JP2018501976A JP2018501976A JP2018524373A5 JP 2018524373 A5 JP2018524373 A5 JP 2018524373A5 JP 2018501976 A JP2018501976 A JP 2018501976A JP 2018501976 A JP2018501976 A JP 2018501976A JP 2018524373 A5 JP2018524373 A5 JP 2018524373A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- construct
- binding
- binding polypeptide
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 344
- 102000036639 antigens Human genes 0.000 claims description 344
- 108091007433 antigens Proteins 0.000 claims description 344
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 157
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 150
- 229920001184 polypeptide Polymers 0.000 claims description 148
- 239000000203 mixture Substances 0.000 claims description 79
- 239000003814 drug Substances 0.000 claims description 78
- 229940079593 drug Drugs 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 59
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 58
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 57
- 150000001413 amino acids Chemical class 0.000 claims description 52
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 46
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 32
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 32
- 238000012986 modification Methods 0.000 claims description 20
- 230000004048 modification Effects 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000000099 in vitro assay Methods 0.000 claims description 13
- 229960003008 blinatumomab Drugs 0.000 claims description 12
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims description 11
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 10
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 10
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 10
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 10
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 10
- 102100024153 Cadherin-15 Human genes 0.000 claims description 9
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 claims description 9
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 7
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 7
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 6
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims description 5
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 102100031013 Transgelin Human genes 0.000 claims description 5
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009490 IgG Receptors Human genes 0.000 claims description 4
- 108010073807 IgG Receptors Proteins 0.000 claims description 4
- 102000029749 Microtubule Human genes 0.000 claims description 4
- 108091022875 Microtubule Proteins 0.000 claims description 4
- 230000002101 lytic effect Effects 0.000 claims description 4
- 210000004688 microtubule Anatomy 0.000 claims description 4
- 229950010127 teplizumab Drugs 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 229940127174 UCHT1 Drugs 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 101000642536 Apis mellifera Venom serine protease 34 Proteins 0.000 claims description 2
- 208000037914 B-cell disorder Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 101000633445 Homo sapiens Structural maintenance of chromosomes protein 2 Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 241000282577 Pan troglodytes Species 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 102100029540 Structural maintenance of chromosomes protein 2 Human genes 0.000 claims description 2
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 2
- 229930188854 dolastatin Natural products 0.000 claims description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 2
- 239000000833 heterodimer Substances 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 229940050282 inebilizumab-cdon Drugs 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 29
- 101100372806 Caenorhabditis elegans vit-3 gene Proteins 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 35
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 239000003053 toxin Substances 0.000 description 7
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000011577 humanized mouse model Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 description 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 1
- WEZNQZHACPSMEF-QEJZJMRPSA-N Ala-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-QEJZJMRPSA-N 0.000 description 1
- 108010080422 CD39 antigen Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193056P | 2015-07-15 | 2015-07-15 | |
| US62/193,056 | 2015-07-15 | ||
| US201562193569P | 2015-07-16 | 2015-07-16 | |
| US62/193,569 | 2015-07-16 | ||
| PCT/CA2016/050839 WO2017008169A1 (en) | 2015-07-15 | 2016-07-15 | Drug-conjugated bi-specific antigen-binding constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018524373A JP2018524373A (ja) | 2018-08-30 |
| JP2018524373A5 true JP2018524373A5 (OSRAM) | 2019-08-22 |
Family
ID=57756601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501976A Pending JP2018524373A (ja) | 2015-07-15 | 2016-07-15 | 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11147886B2 (OSRAM) |
| EP (1) | EP3322735A4 (OSRAM) |
| JP (1) | JP2018524373A (OSRAM) |
| CN (1) | CN108137706A (OSRAM) |
| CA (1) | CA2991799A1 (OSRAM) |
| WO (1) | WO2017008169A1 (OSRAM) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4276116A3 (en) | 2015-04-17 | 2024-01-17 | Amgen Research (Munich) GmbH | Bispecific antibody constructs for cdh3 and cd3 |
| CN107849148B (zh) | 2015-05-21 | 2023-09-19 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| CN110461876B (zh) * | 2017-01-20 | 2024-05-17 | 海德堡医药研究有限责任公司 | 用于耗尽cd137+细胞的组合物和方法 |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| EP3579848B1 (en) | 2017-02-08 | 2024-10-30 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| JP7685821B2 (ja) | 2017-02-20 | 2025-05-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 |
| CA3053749A1 (en) * | 2017-02-28 | 2018-09-07 | Kinki University | Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| MX2019014000A (es) * | 2017-05-23 | 2020-07-29 | Dragonfly Therapeutics Inc | Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor. |
| BR112020005390A2 (pt) * | 2017-09-20 | 2020-09-29 | Mersana Therapeutics, Inc. | composições e métodos para prever a resposta à terapia direcionada ao napi2b |
| KR20200086278A (ko) | 2017-10-18 | 2020-07-16 | 노파르티스 아게 | 선택적 단백질 분해를 위한 조성물 및 방법 |
| TW201922774A (zh) | 2017-11-15 | 2019-06-16 | 瑞士商諾華公司 | 標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法 |
| AU2018375738A1 (en) | 2017-11-30 | 2020-06-11 | Novartis Ag | BCMA-targeting chimeric antigen receptor, and uses thereof |
| WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
| MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| KR20210020903A (ko) | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| SG11202101298XA (en) | 2018-08-08 | 2021-03-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| SG11202101825QA (en) | 2018-08-31 | 2021-03-30 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| IL281683B2 (en) * | 2018-09-25 | 2023-04-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
| WO2020099513A1 (en) * | 2018-11-13 | 2020-05-22 | Lipoxen Technologies Limited | Glycopolysialylation of blinatumomab |
| CN114426578B (zh) * | 2019-02-14 | 2025-03-21 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
| SG11202107825WA (en) | 2019-02-25 | 2021-09-29 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| CN109776683B (zh) * | 2019-03-19 | 2020-04-07 | 益科思特(北京)医药科技发展有限公司 | 一种双特异性抗体及其制备方法与应用 |
| WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| TW202106715A (zh) * | 2019-04-25 | 2021-02-16 | 瑞士商赫孚孟拉羅股份公司 | 藉由多肽鏈交換活化之治療性多特異性多肽 |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| CN110423723A (zh) * | 2019-07-18 | 2019-11-08 | 南方医科大学南方医院 | 一种外周血b细胞系的构建方法及其应用 |
| WO2021055342A1 (en) * | 2019-09-16 | 2021-03-25 | Regents Of The University Of Minnesota | Immunotherapy compounds and methods |
| AR120566A1 (es) | 2019-11-26 | 2022-02-23 | Novartis Ag | Receptores de antígeno quiméricos y sus usos |
| EP4073122A4 (en) * | 2019-12-11 | 2024-03-27 | Cullinan Oncology, Inc. | ANTI-CD19 ANTIBODIES AND MULTI-SPECIFIC BINDING PROTEINS |
| JP7392145B2 (ja) * | 2019-12-20 | 2023-12-05 | 山東博安生物技術股▲ふん▼有限公司 | 免疫療法のためのｔ細胞二重特異性抗体の作製における最適化された抗ｃｄ３アーム |
| IL295413A (en) * | 2020-02-27 | 2022-10-01 | Phanes Therapeutics Inc | Antibodies conjugated with fatty acid molecules and their uses |
| KR20220147109A (ko) | 2020-02-27 | 2022-11-02 | 노파르티스 아게 | 키메라 항원 수용체 발현 세포의 제조 방법 |
| AR121461A1 (es) | 2020-02-27 | 2022-06-08 | Novartis Ag | Métodos para la fabricación de células que expresan el receptor de antígeno quimérico |
| BR112023023650A2 (pt) | 2020-04-04 | 2024-01-30 | Janux Therapeutics Inc | Composições e métodos relacionados a anticorpos ativados por tumores direcionados a egfr e antígenos de células efetoras |
| AR122018A1 (es) | 2020-05-06 | 2022-08-03 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y clec12a |
| AU2021288224A1 (en) | 2020-06-11 | 2023-01-05 | Novartis Ag | ZBTB32 inhibitors and uses thereof |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CN111840571B (zh) * | 2020-08-03 | 2022-09-20 | 杭州皓阳生物技术有限公司 | 一种抗体药物偶联物及其用途 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| US11197910B1 (en) | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
| TW202227124A (zh) | 2020-08-21 | 2022-07-16 | 瑞士商諾華公司 | 用於體內產生ｃａｒ表現細胞的組成物和方法 |
| KR20230128271A (ko) * | 2020-11-20 | 2023-09-04 | 악티늄 파마슈티컬즈, 인코포레이티드 | 고형 암의 치료를 위한 her3 방사선면역요법 |
| TW202237653A (zh) * | 2020-12-09 | 2022-10-01 | 美商詹努克斯治療有限公司 | 與經腫瘤活化之靶定trop2及效應細胞抗原之抗體相關之組合物及方法 |
| US20250262314A1 (en) * | 2021-02-08 | 2025-08-21 | Synaffix B.V. | Multifunctional antibodies |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| JP7708453B2 (ja) * | 2021-03-23 | 2025-07-15 | 広州凌騰生物医薬有限公司 | Ｃｄ３に結合する多重特異性抗原結合タンパク質とその使用方法 |
| US20240384293A1 (en) | 2021-04-27 | 2024-11-21 | Novartis Ag | Viral vector production system |
| WO2022240865A1 (en) * | 2021-05-11 | 2022-11-17 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
| AU2022330406A1 (en) | 2021-08-20 | 2024-03-07 | Novartis Ag | Methods of making chimeric antigen receptor–expressing cells |
| KR20240149403A (ko) * | 2022-02-11 | 2024-10-14 | 선전 엔듀어링 바이오테크 리미티드 | Peg화 항체 하이드록실 함유 약물 접합체 |
| AU2023369684A1 (en) | 2022-10-26 | 2025-04-17 | Novartis Ag | Lentiviral formulations |
| AU2024210908A1 (en) | 2023-01-18 | 2025-08-21 | Tyligand Bioscience (Shanghai) Limited | Antibody-drug conjugate and use thereof |
| WO2024193449A1 (en) * | 2023-03-17 | 2024-09-26 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-her3 and anti-met antibodies and uses thereof |
| WO2024193682A1 (en) * | 2023-03-23 | 2024-09-26 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Anti-tpbg/met antibodies and uses thereof |
| WO2025099489A1 (en) * | 2023-11-10 | 2025-05-15 | Ligachem Biosciences Inc. | Antibody-drug conjugate comprising bispecific antibody specifically binding to cd20 and cd22 and uses thereof |
| WO2025151685A1 (en) * | 2024-01-11 | 2025-07-17 | Systimmune, Inc. | Antibody-auristatin drug conjugate and pharmaceutical use thereof |
| WO2025151684A1 (en) * | 2024-01-11 | 2025-07-17 | Systimmune, Inc. | Antibody-auristatin drug conjugates and methods of making and using thereof |
| WO2025223455A1 (en) | 2024-04-24 | 2025-10-30 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-ptk7/b7h3 antibodies and uses thereof |
| CN119431525B (zh) * | 2024-10-08 | 2025-04-11 | 北京溯本源和生物科技有限公司 | 狂犬病毒g蛋白重组抗原、单克隆抗体及其制备方法和应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| RU2005141512A (ru) | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| EP1701979A2 (en) * | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
| DK2213683T3 (da) | 2004-08-04 | 2013-09-02 | Mentrik Biotech Llc | VARIANT-Fc-REGIONER |
| WO2007097812A2 (en) | 2005-11-03 | 2007-08-30 | Genentech, Inc. | Therapeutic anti-her2 antibody fusion polypeptides |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| EP2027153B1 (en) | 2006-05-25 | 2014-04-30 | Bayer Intellectual Property GmbH | Dimeric molecular complexes |
| MX2009002414A (es) | 2006-09-08 | 2009-05-20 | Medimmune Llc | Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria. |
| US8580263B2 (en) | 2006-11-21 | 2013-11-12 | The Regents Of The University Of California | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
| RU2561457C2 (ru) * | 2007-04-03 | 2015-08-27 | Эмджен Рисерч (Мьюник) Гмбх | Cd3-эпсилон-связывающий домен с межвидовой специфичностью |
| CA2729403A1 (en) * | 2008-06-30 | 2010-01-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| AU2010242338B2 (en) * | 2009-05-01 | 2013-12-19 | Perseus Proteomics Inc. | Anti-cadherin antibody |
| SI2493503T2 (sl) | 2009-10-27 | 2021-04-30 | Amgen Research (Munich) Gmbh | Režim odmerjanja za dajanje cd19xcd3 bispecifičnega protitelesa |
| WO2011056124A1 (en) | 2009-11-04 | 2011-05-12 | Affibody Ab | Her3 binding polypeptides |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| PT2519543T (pt) | 2009-12-29 | 2016-10-07 | Emergent Product Dev Seattle | Proteínas de ligação de heterodímero e suas utilizações |
| EP2552957A4 (en) | 2010-03-29 | 2013-11-20 | Zymeworks Inc | ANTIBODIES WITH REINFORCED OR SUPPRESSIVE ACTIVE FUNCTION |
| CA2800769C (en) | 2010-05-27 | 2021-11-02 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| ME02637B (me) | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| SMT201700250T1 (it) | 2010-11-10 | 2017-07-18 | Amgen Res Munich Gmbh | Prevenzione di effetti avversi provocati da domini leganti cd3 specifici |
| JP6101638B2 (ja) | 2011-03-03 | 2017-03-22 | ザイムワークス，インコーポレイテッド | 多価ヘテロマルチマー足場設計及び構築物 |
| US20140170149A1 (en) * | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| EP2701741B1 (en) | 2011-04-28 | 2020-06-10 | Amgen Research (Munich) GmbH | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| CN109517059B (zh) | 2011-06-30 | 2023-03-28 | 中外制药株式会社 | 异源二聚化多肽 |
| NO2748201T3 (OSRAM) | 2011-08-23 | 2018-05-12 | ||
| WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| AU2013258834B2 (en) | 2012-05-10 | 2017-09-07 | Zymeworks Bc Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain |
| AU2013258844B2 (en) | 2012-05-10 | 2017-12-21 | Zymeworks Bc Inc. | Single-arm monovalent antibody constructs and uses thereof |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| WO2014012082A2 (en) | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design an constructs |
| AU2013289883B2 (en) | 2012-07-13 | 2018-11-01 | Zymeworks Bc Inc. | Bispecific asymmetric heterodimers comprising anti-CD3 constructs |
| CN104640561A (zh) | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| US9382329B2 (en) * | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| EP2925785A4 (en) | 2012-11-28 | 2016-11-16 | Zymeworks Inc | MANIPULATED IMMUNOGLOBULIN HEAVY CHAIN LIGHT CHAIN COUPLES AND USES THEREOF |
| CN105051069B (zh) * | 2013-01-14 | 2019-12-10 | Xencor股份有限公司 | 新型异二聚体蛋白 |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| AU2014262566A1 (en) | 2013-05-08 | 2015-11-12 | Zymeworks Inc. | Bispecific HER2 and HER3 antigen binding constructs |
| MX2016000272A (es) * | 2013-07-12 | 2016-08-03 | Zymeworks Inc | Construcciones de unión a los antígenos cd19 y cd3 biespecificos. |
| CN104341504B (zh) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
| ES3030987T3 (en) | 2013-11-27 | 2025-07-03 | Zymeworks Bc Inc | Bispecific antigen-binding constructs targeting her2 |
| BR112016016114A2 (pt) | 2014-01-15 | 2018-05-22 | Zymeworks Inc | Construtos de ligação a antígeno cd19 e cd3 bi- específico. |
| SG11201609707WA (en) | 2014-07-01 | 2017-01-27 | Pfizer | Bispecific heterodimeric diabodies and uses thereof |
-
2016
- 2016-07-15 CN CN201680053451.9A patent/CN108137706A/zh active Pending
- 2016-07-15 CA CA2991799A patent/CA2991799A1/en not_active Abandoned
- 2016-07-15 WO PCT/CA2016/050839 patent/WO2017008169A1/en not_active Ceased
- 2016-07-15 JP JP2018501976A patent/JP2018524373A/ja active Pending
- 2016-07-15 EP EP16823604.0A patent/EP3322735A4/en not_active Withdrawn
- 2016-07-15 US US15/741,984 patent/US11147886B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524373A5 (OSRAM) | ||
| JP7592660B2 (ja) | 改善された内部移行特性を有する多重特異性抗原結合分子 | |
| US20230105802A1 (en) | Anti-ntb-a antibodies and related compositions and methods | |
| TWI593707B (zh) | Ｃｄ３３抗體類及彼等於治療癌症之用途 | |
| KR102514317B1 (ko) | 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법 | |
| DK3102606T3 (en) | ANTIBODY MEDICINAL CONJUGATES AND IMMUNTOXINES | |
| CN107735105B (zh) | 抗ntb-a抗体和相关组合物以及方法 | |
| US20230235071A1 (en) | Anti-CD30 Antibodies and Methods for Treating CD30+ Cancer | |
| WO2021136483A1 (en) | Anti-trop2 antibodies, antibody-drug conjugates, and application of the same | |
| TWI872065B (zh) | 雙互補位ＦＲ－α抗體及免疫結合物 | |
| US11497769B2 (en) | Anti-CD19 antibodies | |
| TW201840586A (zh) | 用於結合作用之半胱胺酸突變抗體 | |
| JP2024521667A (ja) | 抗－ｃｄ２０５抗体及び免疫チェックポイント・インヒビターを含む組み合わせ医薬 | |
| WO2024258967A1 (en) | Anti-cd5 antibodies and their uses |